A Study in Healthy People to Test How Vicadrostat Affects the Heart

NCT07513207 on ClinicalTrials.gov Phase 1 Boehringer Ingelheim (industry) Started 2026-04-22 Completed

Riskier than 3% of active trials

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

How it ended

Completed on 2026-08-21, after 2026-04-22 start.

The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.

Termination over time, as the model saw it at the start

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-08-21. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

What moved the score

Accepts healthy volunteers: Yes (lowers risk) · Who can join
Design: crossover (lowers risk) · Design
Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: placeboheartprpressurecardiac
Phrases that lowered it: healthyvolunteersmaleopen labelcrossover
Phase: 1 (lowers risk) · Design
Sponsor's past termination rate: 9.3% (raises risk) · Sponsor's track record
Drug's FAERS reports with a death: 11.8% (lowers risk) · Drug's FDA history
Trials the sponsor started in the prior 2 years: 105 (lowers risk) · Sponsor's track record
Sponsor's past trials: 908 (raises risk) · Sponsor's track record
Has a data monitoring committee: No (lowers risk) · Design
Sponsor type: industry (lowers risk) · Sponsor's track record
Disease area, cancer: No (lowers risk) · Disease area
Drug's FAERS reports marked serious: 84.7% (lowers risk) · Drug's FDA history
Number of arms: 4 (lowers risk) · Design
Drug's FAERS reports before start: 27686 (lowers risk) · Drug's FDA history
Primary purpose: treatment (raises risk) · Design
Disease area, neurology: No (lowers risk) · Disease area
Maximum age: 50 (lowers risk) · Who can join
Minimum age: 18 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

The trial

Design

Phase: 1 (typical: 2)
Number of arms: 4 (typical: 2)
Allocation: randomized
Design: crossover (typical: parallel)
Primary purpose: treatment
Blinding: quadruple (typical: none)
Has a data monitoring committee: No (typical: 56% yes)
Responsible party: sponsor
Collaborators: 0
Keywords listed: 0 (typical: 1)

Who can join

Minimum age: 18
Maximum age: 50 (typical: 71)
Sex: all
Accepts healthy volunteers: Yes (typical: 9% yes)

Sponsor's track record

Sponsor type: industry (typical: academic or other)
Sponsor's past trials: 908 (typical: 32)
Sponsor's past termination rate: 9.3% (typical: 9.9%)
Trials the sponsor started in the prior 2 years: 105 (typical: 19)

Drug's FDA history

Drugs with FDA adverse-event history: 2 (typical: 1)
Drug has FAERS history: Yes (typical: 64% yes)
Drug's FAERS reports before start: 27686 (typical: 2148)
Drug's FAERS reports in the prior 12 months: 2459 (typical: 412.5)
Drug's FAERS reports marked serious: 84.7% (typical: 85.6%)
Drug's FAERS reports with a death: 11.8% (typical: 15.9%)

Disease area and drugs

Disease areas: none of the 14 tracked areas
Drugs matched to FDA substances: moxifloxacin, vicadrostat

Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.

Similar finished trials

A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together NCT07035457 · started 2025 · scored riskier than 2% of active trials completed
A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood NCT07133399 · started 2025 · scored riskier than 3% of active trials completed
A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects NCT02117830 · started 2014 · scored riskier than 3% of active trials completed
A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects NCT06310876 · started 2024 · scored riskier than 1% of active trials completed
A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities NCT06107036 · started 2024 · scored riskier than 4% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.